Karolinska Development
1,212 SEK +0,83%1 investor følger denne virksomhed
Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.
Omsætning
2,01 mio.
EBIT %
-174,63 %
P/E
60,6
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
KDEV
Daglig lav / høj pris
1,19 / 1,214
SEK
Markedsværdi
327,33 mio. SEK
Aktieomsætning
114,62 t SEK
Volumen
95 t
Finanskalender
Delårsrapport
15.11.2024
Årsrapport
14.02.2025
Delårsrapport
30.04.2025
Generalforsamling
15.05.2025
Delårsrapport
29.08.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
invoX Pharma Ltd | 47,7 % | 43,9 % |
Worldwide International Investments Ltd | 10,4 % | 9,6 % |
Swedbank Robur Microcap Fond | 3,2 % | 3,0 % |
Styviken Invest AS | 1,9 % | 1,8 % |
Avanza Pension | 1,8 % | 1,7 % |
Stift för främjande&utveckling av medcin forskn | 1,6 % | 9,3 % |
Coastal Investment Management LLC | 0,9 % | 0,8 % |
SEB Investment Management | 0,5 % | 0,5 % |
Handelsbanken Fonder | 0,5 % | 0,5 % |
Nordnet Pensionsförsäkringar | 0,5 % | 0,5 % |
ViserAlle indholdstyper
Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01
Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools